Regatta Bio
1 known investors
Regatta Bio develops precision regulatory T-cell (Treg) therapies aimed at inducing immune tolerance for patients with immune-driven conditions such as chronic graft-versus-host disease, transplant rejection, autoimmune diseases, and inflammatory conditions. The company positions its approach as an alternative to broad immunosuppression across cell transplants, organ transplants, and autoimmunity.
Investors · 1
Frequently asked questions
- What does Regatta Bio do?
- Regatta Bio develops precision regulatory T-cell (Treg) therapies aimed at inducing immune tolerance for patients with immune-driven conditions such as chronic graft-versus-host disease, transplant rejection, autoimmune diseases, and inflammatory conditions. The company positions its approach as an alternative to broad immunosuppression across cell transplants, organ transplants, and autoimmunity.
- Who are Regatta Bio's investors?
- Regatta Bio's investors include Panacea Venture.